首页084990 • KOSDAQ
add
Helixmith Co Ltd
昨日收盘价
₩2,845.00
当日价格范围
₩2,795.00 - ₩2,870.00
年度波幅
₩2,500.00 - ₩7,440.00
市值
1297.51亿 KRW
平均交易量
7.32万
市盈率
-
股息率
-
主要交易所
KOSDAQ
市场资讯
财务信息
损益表
收入
净收入
| (KRW) | 2024年9月info | 年同比变化 |
|---|---|---|
收入 | 18.03亿 | 65.09% |
经营支出 | 58.09亿 | -30.08% |
净收入 | -37.95亿 | 54.16% |
净利润率 | -210.47 | 72.24% |
每股收益 | — | — |
息税折旧摊销前利润 | -39.66亿 | 24.02% |
有效税率 | — | — |
资产负债表
总资产
负债总额
| (KRW) | 2024年9月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 704.53亿 | -16.48% |
总资产 | 1499.03亿 | -34.10% |
负债总额 | 60.75亿 | -79.04% |
权益总额 | 1438.28亿 | — |
发行在外的股份 | 4604.69万 | — |
市净率 | 0.91 | — |
资产回报率 | -8.32% | — |
资本回报率 | -8.66% | — |
现金流
现金净变动
| (KRW) | 2024年9月info | 年同比变化 |
|---|---|---|
净收入 | -37.95亿 | 54.16% |
来自运营的现金 | -45.18亿 | 7.87% |
投资现金 | 320.00亿 | 121.76% |
融资现金 | -668.11万 | 99.86% |
现金净变动 | 278.03亿 | 474.69% |
自由现金流 | 5.23亿 | 107.32% |
简介
Helixmith Co. LTD. is a biotechnology company located in Seoul, South Korea with US presence in San Diego. The company has an extensive gene therapy pipeline, including a non-viral plasmid DNA program for neuromuscular and ischemic disease, a CAR-T program targeting several different types of solid tumors, and an AAV vector program targeting neuromuscular diseases. Helixmith’s lead gene is Engensis, currently in phase III diabetic peripheral neuropathy in the US. Engensis is a plasmid DNA designed to simultaneously express two isoforms of hepatocyte growth factor, HGF 728 and HGF 723. In addition to DPN, Engensis is also being studied in diabetic foot ulcers, amyotrophic lateral sclerosis, coronary artery disease, claudication, and Charcot-Marie-Tooth disease. Wikipedia
CEO
成立时间
11月 1996
员工数量
72
